Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity (Q37049686)

From Wikidata

Jump to navigation Jump to search

scientific article published on October 2007

edit

Language	Label	Description	Also known as
English	Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity	scientific article published on October 2007

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

review article

1 reference

stated in

Europe PubMed Central

title

Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

main subject

obesity

0 references

author name string

Jennifer B Green

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

Mark N Feinglos

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

publication date

1 October 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

published in

Current diabetes report

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

volume

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

page(s)

369-375

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

cites work

Exenatide: a novel approach for treatment of type 2 diabetes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS11892-007-0060-0

retrieved

21 January 2018

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS11892-007-0060-0

retrieved

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FS11892-007-0060-0

retrieved

21 January 2018

Alpha cell function in health and disease: influence of glucagon-like peptide-1.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rimonabant--a selective CB1 antagonist

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term weight loss after diet and exercise: a systematic review

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Contribution of CB1 blockade to the management of high-risk abdominal obesity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin mimetics and DPP-IV inhibitors: new paradigms for the treatment of type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide: a new option for the treatment of type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation of the peripheral endocannabinoid system in human obesity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rimonabant for overweight or obesity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diabetes: assessing the pipeline

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/18173970

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11892-007-0060-0

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

PubMed publication ID

18173970

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18173970

retrieved

17 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37049686&oldid=2199796896"